Skip to main content

Table 1 Demographics

From: Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

  Low-risk PV (n = 1033) High-risk PV (n = 1823) All patients (N = 2856)
Mean (SD) age, years 49.7 (8.6) 69.7 (9.9) 62.5 (13.5)
Age group, n (%), years
 18–34 73 (7.1) 5 (0.3) 78 (2.7)
 35–54 573 (55.5) 86 (4.7) 659 (23.1)
 55–64 387 (37.5) 522 (28.6) 909 (31.8)
  ≥ 65 NA 1210 (66.4) 1210 (42.4)
Sex, n (%)
 Male 757 (73.3) 1125 (61.7) 1882 (65.9)
 Female 276 (26.7) 698 (38.3) 974 (34.1)
Geographic region, n (%)
 South 402 (38.9) 558 (30.6) 960 (33.6)
 North Central 230 (22.3) 499 (27.4) 729 (25.5)
 Northeast 218 (21.1) 482 (26.4) 700 (24.5)
 West 169 (16.4) 270 (14.8) 439 (15.4)
 Unknown 14 (1.4) 14 (0.8) 28 (1.0)
Insurance payer, n (%)
 Commercial 1033 (100) 613 (33.6) 1646 (57.6)
 Medicare 0 1210 (66.4) 1210 (42.4)
Insurance plan type, n (%)
 PPO 669 (64.8) 943 (51.7) 1612 (56.4)
 Comprehensive 47 (4.5) 576 (31.6) 623 (21.8)
 HMO 106 (10.3) 150 (8.2) 256 (9.0)
 POS 83 (8.0) 70 (3.8) 153 (5.4)
 CDHP 72 (7.0) 37 (2.0) 109 (3.8)
 HDHP 32 (3.1) 13 (0.7) 45 (1.6)
 EPO 6 (0.6) 18 (1.0) 24 (0.8)
 POS with capitation 7 (0.7) 2 (0.1) 9 (0.3)
 Unknown 11 (1.1) 14 (0.8) 25 (0.9)
  1. Data assessed on the index date (January 1, 2013)
  2. CDHP consumer-driven health plan, EPO exclusive provider organization, HDHP high-deductible health plan, HMO health maintenance organization, NA not applicable, POS point of service, PPO preferred provider organization, PV polycythemia vera, SD standard deviation